iRadimed Sees Q4 Adj EPS $0.57-$0.61 vs $0.63 Est; Sees Sales $25.000M-$26.500M vs $26.233M Est
iRadimed (NASDAQ:IRMD) is looking for Q4 Adj EPS of $0.57-$0.61 vs $0.63 analyst estimate. sees sales of $25.000 million-$26.500 million vs $26.233 million analyst estimate.
Share
Why It Matters
iRadimed says it will make less money than experts thought it would. When a company misses its targets, watch to see if it keeps improving next quarter.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.